Literature DB >> 33902946

Management of pregnancy after radical trachelectomy.

Yoshifumi Kasuga1, Satoru Ikenoue2, Mamoru Tanaka2, Daigo Ochiai2.   

Abstract

Radical trachelectomy (RT) is a surgery for early-stage cervical cancer treatment that preserves the childbearing ability, and its use has become increasingly common worldwide. Thus, the rate of conception in women who have undergone RT is increasing. However, pregnancy after RT is associated with a higher risk of several obstetric complications such as preterm delivery, preterm premature membrane rupture, and abnormal bleeding from varices at the site of uterovaginal anastomosis. Furthermore, since RT have a residual prophylactic cerclage, it is difficult to manage first- and second-trimester miscarriages. There is little previous data on the management of pregnancy after RT. In this review article, we summarize various management methods and experiences to provide a guide to clinicians for perinatal management after RT.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Cervical Cancer; Cesarean section; Miscarriage; Pregnancy; Trachelectomy; Ultrasound

Mesh:

Year:  2021        PMID: 33902946     DOI: 10.1016/j.ygyno.2021.04.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Prophylactic administration of human amniotic fluid stem cells suppresses inflammation-induced preterm birth via macrophage polarization.

Authors:  Yushi Abe; Daigo Ochiai; Seiji Kanzaki; Yu Sato; Toshimitsu Otani; Satoru Ikenoue; Yoshifumi Kasuga; Mamoru Tanaka
Journal:  Mol Cell Biochem       Date:  2022-07-10       Impact factor: 3.396

2.  Fetal biometric and Doppler measurements following abdominal radical trachelectomy in the second trimester of the pregnancy.

Authors:  Eiri Shima; Mina Itsukaichi; Kosuke Yoshihara; Tatsuya Ishiguro; Kazufumi Haino; Koji Nishino; Nobumichi Nishikawa; Koji Nishijima; Takayuki Enomoto
Journal:  BMC Pregnancy Childbirth       Date:  2022-04-20       Impact factor: 3.105

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.